{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T08:10:47Z","timestamp":1795075847804,"version":"4.10.2"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-01885"],"award-info":[{"award-number":["2019-01885"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010769","name":"Petrus och Augusta Hedlunds Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005701","name":"\u00c5hl\u00e9n-stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008738","name":"Jeanssons Stiftelser","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bertil och Ebon Norlins stiftelse"},{"DOI":"10.13039\/100018850","name":"Gunvor och Josef An\u00e9rs Siftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007464","name":"Torsten S\u00f6derbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007464","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Aggregation of the amyloid-\u03b2 (A\u03b2) peptide in the brain is one of the key pathological events in Alzheimer\u2019s disease (AD). Reducing A\u03b2 levels in the brain by enhancing its degradation is one possible strategy to develop new therapies for AD. Neprilysin (NEP) is a membrane-bound metallopeptidase and one of the major A\u03b2-degrading enzymes. The secreted soluble form of NEP (sNEP) has been previously suggested as a potential protein-therapy degrading A\u03b2 in AD. However, similar to other large molecules, peripherally administered sNEP is unable to reach the brain due to the presence of the blood\u2013brain barrier (BBB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To provide transcytosis across the BBB, we recombinantly fused the TfR binding moiety (scFv8D3) to either sNEP or a previously described variant of NEP (muNEP) suggested to have higher degradation efficiency of A\u03b2 compared to other NEP substrates, but not per se to degrade A\u03b2 more efficiently. To provide long blood half-life, an Fc-based antibody fragment (scFc) was added to the designs, forming sNEP-scFc-scFv8D3 and muNEP-scFc-scFv8D3. The ability of the mentioned recombinant proteins to degrade A\u03b2 was first evaluated in vitro using synthetic A\u03b2 peptides followed by sandwich ELISA. For the in vivo studies, a single injection of 125-iodine-labelled sNEP-scFc-scFv8D3 and muNEP-scFc-scFv8D3 was intravenously administered to a tg-ArcSwe mouse model of AD, using scFc-scFv8D3 protein that lacks NEP as a negative control. Different ELISA setups were applied to quantify A\u03b2 concentration of different conformations, both in brain tissues and blood samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>When tested in vitro, sNEP-scFc-scFv8D3 retained sNEP enzymatic activity in degrading A\u03b2 and both constructs efficiently degraded arctic A\u03b2<jats:italic>.<\/jats:italic>When intravenously injected, sNEP-scFc-scFv8D3 demonstrated 20 times higher brain uptake compared to sNEP. Both scFv8D3-fused NEP proteins significantly reduced aggregated A\u03b2 levels in the blood of tg-ArcSwe mice, a transgenic mouse model of AD, following a single intravenous injection. In the brain, monomeric and oligomeric A\u03b2 were significantly reduced. Both scFv8D3-fused NEP proteins displayed a fast clearance from the brain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A one-time injection of a BBB-penetrating NEP shows the potential to reduce, the likely most toxic, A\u03b2 oligomers in the brain in addition to monomers. Also, A\u03b2 aggregates in the blood were reduced.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13195-022-01132-2","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:03:47Z","timestamp":1670231027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Blood\u2013brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Fadi","family":"Rofo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole G.","family":"Metzendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Suominen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Godec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Sehlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Syv\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Hultqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"issue":"1","key":"1132_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-2001-3111","volume":"3","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe DJ. Alzheimer\u2019s disease results from the cerebral accumulation and cytotoxicity of amyloid &szlig;-protein. J Alzheimers Dis. 2001;3(1):75\u201380.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1132_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jnc.12675","volume":"129","author":"E Dawkins","year":"2014","unstructured":"Dawkins E, Small DH. Insights into the physiological function of the \u03b2-amyloid precursor protein: beyond Alzheimer\u2019s disease. J Neurochem. 2014;129(5):756\u201369.","journal-title":"J Neurochem"},{"issue":"34","key":"1132_CR3","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1523\/JNEUROSCI.1736-09.2009","volume":"29","author":"ML Giuffrida","year":"2009","unstructured":"Giuffrida ML, Caraci F, Pignataro B, Cataldo S, Bona PD, Bruno V, et al. \u03b2-Amyloid monomers are neuroprotective. J Neurosci. 2009;29(34):10582\u20137.","journal-title":"J Neurosci"},{"key":"1132_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fncel.2015.00297","volume":"9","author":"ML Giuffrida","year":"2015","unstructured":"Giuffrida ML, Tomasello MF, Pandini G, Caraci F, Battaglia G, Busceti C, et al. Monomeric \u00df-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons. Front Cell Neurosci. 2015;9:297.","journal-title":"Front Cell Neurosci"},{"issue":"8","key":"1132_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.molmed.2007.06.004","volume":"13","author":"MOW Grimm","year":"2007","unstructured":"Grimm MOW, Grimm HS, Hartmann T. Amyloid beta as a regulator of lipid homeostasis. Trends Mol Med. 2007;13(8):337\u201344.","journal-title":"Trends Mol Med"},{"issue":"1","key":"1132_CR6","doi-asserted-by":"publisher","first-page":"e12684","DOI":"10.1111\/acel.12684","volume":"17","author":"S Zimbone","year":"2018","unstructured":"Zimbone S, Monaco I, Gian\u00ec F, Pandini G, Copani AG, Giuffrida ML, et al. Amyloid Beta monomers regulate cyclic adenosine monophosphate response element binding protein functions by activating type-1 insulin-like growth factor receptors in neuronal cells. Aging Cell. 2018;17(1):e12684.","journal-title":"Aging Cell"},{"issue":"5054","key":"1132_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135.","journal-title":"Science"},{"issue":"5580","key":"1132_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science"},{"issue":"1","key":"1132_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41467-019-09477-3","volume":"10","author":"S De","year":"2019","unstructured":"De S, Wirthensohn DC, Flagmeier P, Hughes C, Aprile FA, Ruggeri FS, et al. Different soluble aggregates of A\u03b242 can give rise to cellular toxicity through different mechanisms. Nat Commun. 2019;10(1):1541.","journal-title":"Nat Commun"},{"issue":"6","key":"1132_CR10","doi-asserted-by":"publisher","first-page":"38187","DOI":"10.1038\/srep38187","volume":"5","author":"TJ Esparza","year":"2016","unstructured":"Esparza TJ, Wildburger NC, Jiang H, Gangolli M, Cairns NJ, Bateman RJ, et al. Soluble amyloid-beta aggregates from human Alzheimer\u2019s disease brains. Sci Rep. 2016;5(6):38187.","journal-title":"Sci Rep"},{"issue":"3\u20134","key":"1132_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbrc.2012.10.129","volume":"429","author":"Y He","year":"2012","unstructured":"He Y, Zheng MM, Ma Y, Han XJ, Ma XQ, Qu CQ, et al. Soluble oligomers and fibrillar species of amyloid \u03b2-peptide differentially affect cognitive functions and hippocampal inflammatory response. Biochem Biophys Res Commun. 2012;429(3\u20134):125\u201330.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1132_CR12","doi-asserted-by":"publisher","first-page":"e32014","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"D Sehlin","year":"2012","unstructured":"Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, et al. Large aggregates are the major soluble A\u03b2 species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2):e32014.","journal-title":"PLoS One"},{"issue":"3","key":"1132_CR13","doi-asserted-by":"publisher","first-page":"fcab147","DOI":"10.1093\/braincomms\/fcab147","volume":"3","author":"DI Sideris","year":"2021","unstructured":"Sideris DI, Danial JSH, Emin D, Ruggeri FS, Xia Z, Zhang YP, et al. Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer\u2019s disease. Brain Commun. 2021;3(3):fcab147.","journal-title":"Brain Commun"},{"issue":"12","key":"1132_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1517\/14712598.7.12.1853","volume":"7","author":"B Spencer","year":"2007","unstructured":"Spencer B, Rockenstein E, Crews L, Marr R, Masliah E. Novel strategies for Alzheimer\u2019s disease treatment. Expert Opin Biol Ther. 2007;7(12):1853\u201367.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1132_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801\u2014the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1132_CR16","doi-asserted-by":"publisher","first-page":"e0229850","DOI":"10.1371\/journal.pone.0229850","volume":"15","author":"CR Campos","year":"2020","unstructured":"Campos CR, Kemble AM, Niewoehner J, Freskg\u00e5rd PO, Urich E. Brain shuttle neprilysin reduces central amyloid-\u03b2 levels. PLoS One. 2020;15(3):e0229850.","journal-title":"PLoS One"},{"issue":"2","key":"1132_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.7150\/thno.50263","volume":"11","author":"F Rofo","year":"2021","unstructured":"Rofo F, Ugur Yilmaz C, Metzendorf N, Gustavsson T, Beretta C, Erlandsson A, et al. Enhanced neprilysin-mediated degradation of hippocampal A\u03b242 with a somatostatin peptide that enters the brain. Theranostics. 2021;11(2):789\u2013804.","journal-title":"Theranostics"},{"issue":"6","key":"1132_CR18","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s11064-019-02756-x","volume":"44","author":"NL Sikanyika","year":"2019","unstructured":"Sikanyika NL, Parkington HC, Smith AI, Kuruppu S. Powering amyloid beta degrading enzymes: a possible therapy for Alzheimer\u2019s disease. Neurochem Res. 2019;44(6):1289\u201396.","journal-title":"Neurochem Res"},{"issue":"11","key":"1132_CR19","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/NEN.0b013e3182345e46","volume":"70","author":"JS Miners","year":"2011","unstructured":"Miners JS, Barua N, Kehoe PG, Gill S, Love S. A\u03b2-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol. 2011;70(11):944\u201359.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"1132_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/j.1460-2075.1987.tb02370.x","volume":"6","author":"A Devault","year":"1987","unstructured":"Devault A, Lazure C, Nault C, Le Moual H, Seidah NG, Chr\u00e9tien M, et al. Amino acid sequence of rabbit kidney neutral endopeptidase 24.11 (enkephalinase) deduced from a complementary DNA. EMBO J. 1987;6(5):1317\u201322.","journal-title":"EMBO J"},{"issue":"3","key":"1132_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/bj1370477","volume":"137","author":"MA Kerr","year":"1974","unstructured":"Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J. 1974;137(3):477\u201388.","journal-title":"Biochem J"},{"issue":"1","key":"1132_CR22","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/srep01472","volume":"3","author":"N Iwata","year":"2013","unstructured":"Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, et al. Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep. 2013;3(1):1472.","journal-title":"Sci Rep"},{"issue":"2","key":"1132_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0304-3940(00)01675-X","volume":"297","author":"K Yasojima","year":"2001","unstructured":"Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of \u03b2-amyloid peptide. Neurosci Lett. 2001;297(2):97\u2013100.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1132_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1471-4159.2010.06899.x","volume":"115","author":"S Wang","year":"2010","unstructured":"Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS. Expression and functional profiling of neprilysin, insulin degrading enzyme and endothelin converting enzyme in prospectively studied elderly and Alzheimer\u2019s brain. J Neurochem. 2010;115(1):47\u201357.","journal-title":"J Neurochem"},{"issue":"2","key":"1132_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbrc.2014.01.158","volume":"446","author":"S Kuruppu","year":"2014","unstructured":"Kuruppu S, Rajapakse NW, Minond D, Smith AI. Production of soluble Neprilysin by endothelial cells. Biochem Biophys Res Commun. 2014;446(2):423\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1132_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0196-9781(95)00021-B","volume":"16","author":"S Howell","year":"1995","unstructured":"Howell S, Nalbantoglu J, Crine P. Neutral endopeptidase can hydrolyze beta-amyloid(1\u201340) but shows no effect on beta-amyloid precursor protein metabolism. Peptides. 1995;16(4):647\u201352.","journal-title":"Peptides"},{"issue":"5521","key":"1132_CR27","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1126\/science.1059946","volume":"292","author":"N Iwata","year":"2001","unstructured":"Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain A\u03b2 by neprilysin. Science. 2001;292(5521):1550\u20132.","journal-title":"Science"},{"issue":"3","key":"1132_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jnr.10390","volume":"70","author":"N Iwata","year":"2002","unstructured":"Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A\u03b2-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002;70(3):493\u2013500.","journal-title":"J Neurosci Res"},{"issue":"6","key":"1132_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/oxfordjournals.jbchem.a022839","volume":"128","author":"Y Takaki","year":"2000","unstructured":"Takaki Y, Iwata N, Tsubuki S, Taniguchi S, Toyoshima S, Lu B, et al. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J Biochem (Tokyo). 2000;128(6):897\u2013902.","journal-title":"J Biochem (Tokyo)"},{"issue":"8","key":"1132_CR30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/jnr.21074","volume":"84","author":"R Madani","year":"2006","unstructured":"Madani R, Poirier R, Wolfer DP, Welzl H, Groscurth P, Lipp HP, et al. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res. 2006;84(8):1871\u20138.","journal-title":"J Neurosci Res"},{"issue":"1","key":"1132_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bbr.2005.10.014","volume":"168","author":"A Mouri","year":"2006","unstructured":"Mouri A, Zou LB, Iwata N, Saido TC, Wang D, Wang MW, et al. Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid \u03b2 and impairment of learning and memory. Behav Brain Res. 2006;168(1):83\u201391.","journal-title":"Behav Brain Res"},{"issue":"3","key":"1132_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0304-3940(03)00902-9","volume":"350","author":"AJ Newell","year":"2003","unstructured":"Newell AJ, Sue LI, Scott S, Rauschkolb PK, Walker DG, Potter PE, et al. Thiorphan-induced neprilysin inhibition raises amyloid beta levels in rabbit cortex and cerebrospinal fluid. Neurosci Lett. 2003;350(3):178\u201380.","journal-title":"Neurosci Lett"},{"issue":"6","key":"1132_CR33","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0896-6273(03)00787-6","volume":"40","author":"MA Leissring","year":"2003","unstructured":"Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40(6):1087\u201393.","journal-title":"Neuron"},{"issue":"6","key":"1132_CR34","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1523\/JNEUROSCI.23-06-01992.2003","volume":"23","author":"RA Marr","year":"2003","unstructured":"Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci Off J Soc Neurosci. 2003;23(6):1992\u20136.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"4","key":"1132_CR35","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.bbrc.2016.06.103","volume":"477","author":"JH Oh","year":"2016","unstructured":"Oh JH, Choi S, Shin J, Park JS. Protective effect of recombinant soluble neprilysin against \u03b2-amyloid induced neurotoxicity. Biochem Biophys Res Commun. 2016;477(4):614\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1529","key":"1132_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.brainres.2013.05.045","volume":"5","author":"MH Park","year":"2013","unstructured":"Park MH, Lee JK, Choi S, Ahn J, Jin HK, Park JS, et al. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer\u2019s disease mice. Brain Res. 2013;5(1529):113\u201324.","journal-title":"Brain Res"},{"issue":"184","key":"1132_CR37","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","volume":"01","author":"XT Fang","year":"2019","unstructured":"Fang XT, Hultqvist G, Meier SR, Antoni G, Sehlin D, Syv\u00e4nen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage. 2019;01(184):881\u20138.","journal-title":"Neuroimage"},{"issue":"2","key":"1132_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"Hultqvist G, Syv\u00e4nen S, Fang XT, Lannfelt L, Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7(2):308\u201318.","journal-title":"Theranostics"},{"issue":"1","key":"1132_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-018-0377-8","volume":"10","author":"S Syv\u00e4nen","year":"2018","unstructured":"Syv\u00e4nen S, Hultqvist G, Gustavsson T, Gumucio A, Laudon H, S\u00f6derberg L, et al. Efficient clearance of A\u03b2 protofibrils in A\u03b2PP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimers Res Ther. 2018;10(1):49.","journal-title":"Alzheimers Res Ther"},{"issue":"143","key":"1132_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","volume":"1","author":"S Gustafsson","year":"2018","unstructured":"Gustafsson S, Gustavsson T, Roshanbin S, Hultqvist G, Hammarlund-Udenaes M, Sehlin D, et al. Blood-brain barrier integrity in a mouse model of Alzheimer\u2019s disease with or without acute 3D6 immunotherapy. Neuropharmacology. 2018;1(143):1\u20139.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1132_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40035-020-00214-1","volume":"9","author":"T Gustavsson","year":"2020","unstructured":"Gustavsson T, Syv\u00e4nen S, O\u2019Callaghan P, Sehlin D. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-\u03b2 antibody in a mouse model of Alzheimer\u2019s disease. Transl Neurodegener. 2020;9(1):37.","journal-title":"Transl Neurodegener"},{"issue":"184","key":"1132_CR42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","volume":"1","author":"XT Fang","year":"2019","unstructured":"Fang XT, Hultqvist G, Meier SR, Antoni G, Sehlin D, Syv\u00e4nen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage. 2019;1(184):881\u20138.","journal-title":"Neuroimage"},{"issue":"6","key":"1132_CR43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ejhf.799","volume":"19","author":"E D\u2019Elia","year":"2017","unstructured":"D\u2019Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail. 2017;19(6):710\u20137.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"1132_CR44","doi-asserted-by":"publisher","first-page":"e104001","DOI":"10.1371\/journal.pone.0104001","volume":"9","author":"CI Webster","year":"2014","unstructured":"Webster CI, Burrell M, Olsson LL, Fowler SB, Digby S, Sandercock A, et al. Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer\u2019s disease. PLoS One. 2014;9(8):e104001.","journal-title":"PLoS One"},{"issue":"1","key":"1132_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neurobiolaging.2004.12.007","volume":"27","author":"A Lord","year":"2006","unstructured":"Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LNG. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27(1):67\u201377.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"1132_CR46","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nn0901-887","volume":"4","author":"C Nilsberth","year":"2001","unstructured":"Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The \u2018Arctic\u2019 APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced A\u03b2 protofibril formation. Nat Neurosci. 2001;4(9):887\u201393.","journal-title":"Nat Neurosci"},{"issue":"4","key":"1132_CR47","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1021\/ci500015m","volume":"54","author":"D Pope","year":"2014","unstructured":"Pope D, Madura JD, Cascio M. \u03b2-Amyloid and neprilysin computational studies identify critical residues implicated in binding specificity. J Chem Inf Model. 2014;54(4):1157\u201365.","journal-title":"J Chem Inf Model"},{"key":"1132_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12575-017-0060-7","volume":"19","author":"XT Fang","year":"2017","unstructured":"Fang XT, Sehlin D, Lannfelt L, Syv\u00e4nen S, Hultqvist G. Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells. Biol Proced Online. 2017;19:11.","journal-title":"Biol Proced Online"},{"issue":"1","key":"1132_CR49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40035-021-00258-x","volume":"10","author":"F Rofo","year":"2021","unstructured":"Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja AM, et al. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Transl Neurodegener. 2021;10(1):38.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"1132_CR50","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, Sehlin D, Johansson AS, Nilsson LNG, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103(1):334\u201345.","journal-title":"J Neurochem"},{"issue":"1","key":"1132_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1042\/bj0890114","volume":"89","author":"F Greenwood","year":"1963","unstructured":"Greenwood F, Hunter W, Glover J. The preparation of 131 I-labelled human growth hormone of high specific radioactivity. Biochem J. 1963;89(1):114\u201323.","journal-title":"Biochem J"},{"issue":"7","key":"1132_CR52","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671\u20135.","journal-title":"Nat Methods"},{"issue":"1","key":"1132_CR53","doi-asserted-by":"publisher","first-page":"e16575","DOI":"10.1371\/journal.pone.0016575","volume":"6","author":"B Spencer","year":"2011","unstructured":"Spencer B, Marr RA, Gindi R, Potkar R, Michael S, Adame A, et al. Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer\u2019s disease. PLoS One. 2011;6(1):e16575.","journal-title":"PLoS One"},{"issue":"4","key":"1132_CR54","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/j.1742-4658.2008.06836.x","volume":"276","author":"A Lord","year":"2009","unstructured":"Lord A, Englund H, S\u00f6derberg L, Tucker S, Clausen F, Hillered L, et al. Amyloid-\u03b2 protofibril levels correlate with spatial learning in Arctic Alzheimer\u2019s disease transgenic mice. FEBS J. 2009;276(4):995\u20131006.","journal-title":"FEBS J"},{"issue":"1","key":"1132_CR55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12987-021-00257-0","volume":"18","author":"R Faresj\u00f6","year":"2021","unstructured":"Faresj\u00f6 R, Bonvicini G, Fang XT, Aguilar X, Sehlin D, Syv\u00e4nen S. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size. Fluids Barriers CNS. 2021;18(1):26.","journal-title":"Fluids Barriers CNS"},{"key":"1132_CR56","doi-asserted-by":"crossref","unstructured":"Morrison J, Metzendorf N, Rofo F, Petrovic A, Hultqvist G. A single chain fragment constant (scFc) design enables easy production of a monovalent BBB transporter and provides an improved brain uptake at elevated doses. Submitted. 2022.","DOI":"10.1111\/jnc.15768"},{"issue":"1","key":"1132_CR57","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1038\/s41467-018-05068-w","volume":"9","author":"M Jin","year":"2018","unstructured":"Jin M, O\u2019Nuallain B, Hong W, Boyd J, Lagomarsino VN, O\u2019Malley TT, et al. An in vitro paradigm to assess potential anti-A\u03b2 antibodies for Alzheimer\u2019s disease. Nat Commun. 2018;9(1):2676.","journal-title":"Nat Commun"},{"issue":"2","key":"1132_CR58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0304-3940(03)00898-X","volume":"350","author":"H Kanemitsu","year":"2003","unstructured":"Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid \u03b2 peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett. 2003;350(2):113\u20136.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1132_CR59","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1038\/srep09649","volume":"5","author":"GAN Crespi","year":"2015","unstructured":"Crespi GAN, Hermans SJ, Parker MW, Miles LA. Molecular basis for mid-region amyloid-\u03b2 capture by leading Alzheimer\u2019s disease immunotherapies. Sci Rep. 2015;5(1):9649.","journal-title":"Sci Rep"},{"issue":"1","key":"1132_CR60","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajpath.2010.11.012","volume":"178","author":"D Hafez","year":"2011","unstructured":"Hafez D, Huang JY, Huynh AM, Valtierra S, Rockenstein E, Bruno AM, et al. Neprilysin-2 is an important \u03b2-amyloid degrading enzyme. Am J Pathol. 2011;178(1):306\u201312.","journal-title":"Am J Pathol"},{"issue":"13","key":"1132_CR61","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1021\/acschemneuro.1c00303","volume":"12","author":"F Rofo","year":"2021","unstructured":"Rofo F, Sandbaumh\u00fcter FA, Chourlia A, Metzendorf NG, Morrison JI, Syv\u00e4nen S, et al. Wide-ranging effects on the brain proteome in a transgenic mouse model of Alzheimer\u2019s disease following treatment with a brain-targeting somatostatin peptide. ACS Chem Neurosci. 2021;12(13):2529\u201341.","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"1132_CR62","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/jnr.22796","volume":"90","author":"K Sato","year":"2012","unstructured":"Sato K, Tanabe C, Yonemura Y, Watahiki H, Zhao Y, Yagishita S, et al. Localization of mature neprilysin in lipid rafts. J Neurosci Res. 2012;90(4):870\u20137.","journal-title":"J Neurosci Res"},{"issue":"39","key":"1132_CR63","doi-asserted-by":"publisher","first-page":"37314","DOI":"10.1074\/jbc.M305627200","volume":"278","author":"MA Leissring","year":"2003","unstructured":"Leissring MA, Lu A, Condron MM, Teplow DB, Stein RL, Farris W, et al. Kinetics of amyloid \u03b2-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays *. J Biol Chem. 2003;278(39):37314\u201320.","journal-title":"J Biol Chem"},{"issue":"24","key":"1132_CR64","doi-asserted-by":"publisher","first-page":"21895","DOI":"10.1074\/jbc.M008511200","volume":"276","author":"K Shirotani","year":"2001","unstructured":"Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, et al. Neprilysin degrades both amyloid \u03b2 peptides 1\u201340 and 1\u201342 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases *. J Biol Chem. 2001;276(24):21895\u2013901.","journal-title":"J Biol Chem"},{"key":"1132_CR65","doi-asserted-by":"crossref","unstructured":"Rosa A de la, Metzendorf NG, Morrison JI, Faresj\u00f6 R, Rofo F, Petrovic A, et al. Introducing or removing heparan sulfate binding sites does not alter brain uptake of the blood-brain barrier shuttle scFv8D3. In Review; 2022 Oct [cited 25 Oct 2022]. Available from: https:\/\/www.researchsquare.com\/article\/rs-2166577\/v1","DOI":"10.21203\/rs.3.rs-2166577\/v1"},{"issue":"3","key":"1132_CR66","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2353\/ajpath.2009.080345","volume":"174","author":"EC Dempsey","year":"2009","unstructured":"Dempsey EC, Wick MJ, Karoor V, Barr EJ, Tallman DW, Wehling CA, et al. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Pathol. 2009;174(3):782\u201396.","journal-title":"Am J Pathol"},{"issue":"4","key":"1132_CR67","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1046\/j.1365-2222.1999.00462.x","volume":"29","author":"VH van der Velden","year":"1999","unstructured":"van der Velden VH, Hulsmann AR. Peptidases: structure, function and modulation of peptide-mediated effects in the human lung. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 1999;29(4):445\u201356.","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"issue":"2","key":"1132_CR68","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/brain\/awt308","volume":"137","author":"SJ Henderson","year":"2014","unstructured":"Henderson SJ, Andersson C, Narwal R, Janson J, Goldschmidt TJ, Appelkvist P, et al. Sustained peripheral depletion of amyloid-\u03b2 with a novel form of neprilysin does not affect central levels of amyloid-\u03b2. Brain. 2014;137(2):553\u201364.","journal-title":"Brain"},{"issue":"6","key":"1132_CR69","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1523\/JNEUROSCI.3407-12.2013","volume":"33","author":"JR Walker","year":"2013","unstructured":"Walker JR, Pacoma R, Watson J, Ou W, Alves J, Mason DE, et al. Enhanced proteolytic clearance of plasma A\u03b2 by peripherally administered neprilysin does not result in reduced levels of brain A\u03b2 in mice. J Neurosci. 2013;33(6):2457\u201364.","journal-title":"J Neurosci"},{"issue":"9373","key":"1132_CR70","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/S0140-6736(03)13555-6","volume":"361","author":"S Tsubuki","year":"2003","unstructured":"Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet Lond Engl. 2003;361(9373):1957\u20138.","journal-title":"Lancet Lond Engl"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01132-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T13:19:00Z","timestamp":1701523140000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01132-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01132-2","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures described in this paper were approved by the Uppsala County Animal Ethical Committee following the ethical guidelines and having the ethical permission number: #5.8.18\u201313350\/17 and #5.8.18\u201320401\/2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}